Work

NIH Recombinant DNA Advisory Committee Continues to Ponder Adverse Event Associated With AAV Gene Therapy Trial

Year: 2008

Type: article

Abstract: At the 3 December 2007 meeting of the National Institutes of Health Recombinant DNA Advisory Committee (NIH RAC), additional information concerning the death of a study participant in the Targeted Genetics gene therapy trial was presented (see previous editorial in Molecular Therapy1). The trial evaluated the effects of delivery of an adeno‐associated virus (AAV) vector to rheumatoid arthritis patients. The therapy involved intra‐articular injection of an AAV2 vector encoding a fusion of the IgG1 Fc and tumor necrosis factor‐α (TNF‐α) receptor.

Source: Molecular Therapy

DOI: 10.1038/mt.2008.2

Author: David A Williams

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500

OpenAlex ID: W2013466896

FWCI: 0.885

Cites: 1

Cited by: 5

Related to: 10